Ferucarbotran versus Gd-DTPA-enhanced MR imaging in the detection of focal hepatic lesions

World Journal of Gastroenterology

Volumn 13, Issue 36, 2007, Pages 4891-4896

  Cheng, Wei Zhong ^a   Zeng, Meng Su ^a   Yan, Fu Hua ^a   Rao, Shen Xiang ^a   Shen, Ji Zhang ^a   Chen, Cai Zhong ^a   Zhang, Shu Jie ^a   Shi, Wei Bin ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Contrast media; Liver disease; Magnetic resonance imaging; Superara magnetic iron oxide

Indexed keywords

FERUCARBOTRAN; GADOLINIUM PENTETATE; SUPERPARAMAGNETIC IRON OXIDE; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; IMAGE ANALYSIS; IMAGE ENHANCEMENT; INTERMETHOD COMPARISON; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; SENSITIVITY ANALYSIS; STATISTICAL SIGNIFICANCE; UNSPECIFIED SIDE EFFECT;

EID: 34848823151     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v13.i36.4891     Document Type: Article

References (28)

1. Zavadsky KE, Lee YT. Liver metastases from colorectal carcinoma: incidence, resectability, and survival results. Am Surg 1994; 60: 929-933
2. Poon RT, Fan ST. Hepatectomy for hepatocellular carcinoma: patient selection and postoperative outcome. Liver Transpl 2004; 10: S39-S45
3. Schwartz M. Liver transplantation in patients with hepatocellular carcinoma. Liver Transpl 2004; 10: S81-S85
4. Yamamoto J, Okada S, Shimada K, Okusaka T, Yamasaki S, Ueno H, Kosuge T. Treatment strategy for small hepatocellular carcinoma: comparison of long-term results after percutaneous ethanol injection therapy and surgical resection. Hepatology 2001; 34: 707-713
5. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003; 37: 429-442
6. Larson RE, Semelka RC. Magnetic resonance imaging of the liver. Top Magn Reson Imaging 1995; 7: 71-81
7. Ward J, Baudouin CJ, Ridgway JP, Robinson PT. Magnetic resonance imaging in the detection of focal liver lesions: comparison of dynamic contrast-enhanced TurboFLASH and T2 weighted spin echo images. Br J Radiol 1995; 68: 463-470
8. Baron RL. Detection of liver neoplasms: techniques and outcomes. Abdom Imaging 1994; 19: 320-324
9. Pauleit D, Textor J, Bachmann R, Conrad R, Flacke S, Layer G, Kreft B, Schild H. Hepatocellular carcinoma: detection with gadolinium- and ferumoxides-enhanced MR imaging of the liver. Radiology 2002; 222: 73-80
10. Reimer P, Rummeny EJ, Daldrup HE, Balzer T, Tombach B, Berns T, Peters PE. Clinical results with Resovist: a phase 2 clinical trial. Radiology 1995; 195: 489-496
11. Kopp AF, Laniado M, Dammann F, Stern W, Gronewaller E, Balzer T, Schimpfky C, Claussen CD. MR imaging of the liver with Resovist: safety, efficacy, and pharmacodynamic properties. Radiology 1997; 204: 749-756
12. Josephson L, Lewis J, Jacobs P, Hahn PF, Stark DD. The effects of iron oxides on proton relaxivity. Magn Reson Imaging 1988; 6: 647-653
13. Hamm B, Staks T, Taupitz M, Maibauer R, Speidel A, Huppertz A, Frenzel T, Lawaczeck R, Wolf KJ, Lange L. Contrast-enhanced MR imaging of liver and spleen: first experience in humans with a new superparamagnetic iron oxide. J Magn Reson Imaging 1994; 4: 659-668
14. McLachlan SJ, Morris MR, Lucas MA, Fisco RA, Eakins MN, Fowler DR, Scheetz RB, Olukotun AY. Phase I clinical evaluation of a new iron oxide MR contrast agent. J Magn Reson Imaging 1994; 4: 301-307
15. Weissleder R, Stark DD, Engelstad BL, Bacon BR, Compton CC, White DL, Jacobs P, Lewis J. Superparamagnetic iron oxide: pharmacokinetics and toxicity. AJR Am J Roentgenol 1989; 152: 167-173
16. Matsuo M, Kanematsu M, Itoh K, Ito K, Maetani Y, Kondo H, Kako N, Matsunaga N, Hoshi H, Shiraishi J. Detection of malignant hepatic tumors: comparison of gadolinium-and ferumoxide-enhanced MR imaging. AJR Am J Roentgenol 2001; 177: 637-643
17. Denys A, Arrive L, Servois V, Dubray B, Najmark D, Sibert A, Menu Y. Hepatic tumors: detection and characterization at 1-T MR imaging enhanced with AMI-25. Radiology 1994; 193: 665-669
18. Blakeborough A, Ward J, Wilson D, Griffiths M, Kajiya Y, Guthrie JA, Robinson PJ. Hepatic lesion detection at MR imaging: a comparative study with four sequences. Radiology 1997; 203: 759-765
19. Shamsi K, Balzer T, Saini S, Ros PR, Nelson RC, Carter EC, Tollerfield S, Niendorf HP. Superparamagnetic iron oxide particles (SH U 555 A): evaluation of efficacy in three doses for hepatic MR imaging. Radiology 1998; 206: 365-371
20. Thornbury JR. Eugene W. Caldwell Lecture. Clinical efficacy of diagnostic imaging: love it or leave it. AJR Am J Roentgenol 1994; 162: 1-8
21. Ros PR, Freeny PC, Harms SE, Seltzer SE, Davis PL, Chan TW, Stillman AE, Muroff LR, Runge VM, Nissenbaum MA. Hepatic MR imaging with ferumoxides: a multicenter clinical trial of the safety and efficacy in the detection of focal hepatic lesions. Radiology 1995; 196: 481-488
22. Okon E, Pouliquen D, Okon P, Kovaleva ZV, Stepanova TP, Lavit SG, Kudryavtsev BN, Jallet P. Biodegradation of magnetite dextran nanoparticles in the rat. A histologic and biophysical study. Lab Invest 1994; 71: 895-903
23. Reimer P, Allkemper T, Matuszewski L, Balzer T. Contrast-enhanced 3D-MRA of the upper abdomen with a bolus-injectable SPIO (SH U 555 A). J Magn Reson Imaging 1999; 10: 65-71
24. Lutz AM, Willmann JK, Goepfert K, Marincek B, Weishaupt D. Hepatocellular carcinoma in cirrhosis: enhancement patterns at dynamic gadolinium- and superparamagnetic iron oxide-enhanced T1-weighted MR imaging. Radiology 2005; 237: 520-528
25. Jung CW, Jacobs P. Physical and chemical properties of superparamagnetic iron oxide MR contrast agents: ferumoxides, ferumoxtran, ferumoxsil. Magn Reson Imaging 1995; 13: 661-674
26. Paley MR, Mergo PJ, Torres GM, Ros PR. Characterization of focal hepatic lesions with ferumoxides-enhanced T2-weighted MR imaging. AJR Am J Roentgenol 2000; 175: 159-163
27. Imai Y, Murakami T, Yoshida S, Nishikawa M, Ohsawa M, Tokunaga K, Murata M, Shibata K, Zushi S, Kurokawa M, Yonezawa T, Kawata S, Takamura M, Nagano H, Sakon M, Monden M, Wakasa K, Nakamura H. Superparamagnetic iron oxide-enhanced magnetic resonance images of hepatocellular carcinoma: correlation with histological grading. Hepatology 2000; 32: 205-212
28. Kim SH, Choi D, Kim SH, Lim JH, Lee WJ, Kim MJ, Lim HK, Lee SJ. Ferucarbotran-enhanced MRI versus triple-phase MDCT for the preoperative detection of hepatocellular carcinoma. AJR Am J Roentgenol 2005; 184: 1069-1076